Status:
COMPLETED
Primary Care Audit of Global Risk Management
Lead Sponsor:
Canadian Collaborative Research Network
Collaborating Sponsors:
AstraZeneca
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
40+ years
Brief Summary
1. Assessing the perception of Canadian Primary Care Physicians towards global cardiovascular risk assessment. 2. Correlating physician perceptions to actual practice data, gathered via a retrospectiv...
Detailed Description
The majority of cardiovascular events occur in people with low to intermediate Framingham Risk Score. Despite evidence-based guidelines, the appropriate use of lipid-lowering therapies in this populat...
Eligibility Criteria
Inclusion
- Men more than or equal to 40 yrs old and women more than or equal to 50 yrs old;
- No previous history of atherosclerosis( angina, TIA, myocardial infarction, stroke, peripheral arterial disease);
- Non-diabetic;
- Absence of lipid lowering treatment (current or past).
Exclusion
- Known history of atherosclerosis or diabetes;
- Use of lipid lowering therapies (statins, ezetimibe, fibrates, niacin, fish oil);
- Use of postmenopausal hormone replacement therapy;
- Use of immunosuppressant's or steroids;
- Active liver disease or hepatic dysfunction(ALT\>2times the ULN);
- Active renal disease (baseline Creatinine \>170 umol/L);
- History of malignancy within the past 5-years;
- Chronic inflammatory conditions such as arthritis, lupus or inflammatory bowel disease;
- Known alcohol or drug abuse;
- Failure to provide informed consent.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
3015 Patients enrolled
Trial Details
Trial ID
NCT00950703
Start Date
March 1 2009
End Date
September 1 2015
Last Update
October 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CCRN
Brampton, Ontario, Canada, L6Z 4N5